RTP Mobile Logo
Submitted by web@researchtop... on Mon, 10/22/2018 - 14:45
LCU318

Interview with David R Spigel, MD

Track 1: Case: A 73-year-old man with recurrent small cell lung cancer (SCLC) receives ipilimumab/nivolumab on a clinical trial
Track 2: Management of immune checkpoint inhibitor-associated rash
Track 3: Correlation between toxicity and treatment benefit for patients receiving immune checkpoint inhibitors
Track 4: Clinical experience with dermatologic side effects of checkpoint inhibitors
Track 5: Second-line therapy options for metastatic SCLC
Track 6: Perspective on ipilimumab/nivolumab dosing and therapy-associated toxicities
Track 7: Activity, side effects and ongoing investigation of the antibody-drug conjugate rovalpituzumab tesirine (Rova-T) in DLL3-positive SCLC
Track 8: Clinical experience with Rova-T-associated edema
Track 9: Results of the Phase III KEYNOTE-407 trial evaluating the addition of pembrolizumab to carboplatin with paclitaxel or nab paclitaxel as first-line therapy for metastatic squamous non-small cell lung cancer (NSCLC)
Track 10: KEYNOTE-042: Overall survival benefit with pembrolizumab versus platinum-based chemotherapy as first-line treatment for locally advanced or metastatic NSCLC with a PD-L1 tumor proportion score (TPS) of 1% or higher
Track 11: Clinical implications of the KEYNOTE-042 results; perspective on the future clinical utility of TPS
Track 12: Evolution of first-line checkpoint inhibitor-based treatment for metastatic nonsquamous NSCLC with and without targetable tumor mutations
Track 13: Selection of checkpoint inhibitor-based regimens for patients experiencing disease progression on an EGFR tyrosine kinase inhibitor (TKI)
Track 14: Case: A 57-year-old man with Stage IIIA squamous NSCLC receives chemoradiation therapy followed by durvalumab
Track 15: Ongoing studies of checkpoint inhibitors in the (neo)adjuvant setting
Track 16: PACIFIC trial: Efficacy and tolerability of durvalumab after chemoradiation therapy for unresectable Stage III NSCLC
Track 17: Management of chemoradiation therapy-associated pneumonitis
Track 18: Perspective on the synergy of durvalumab and chemoradiation therapy
Track 19: Use of chemoradiation therapy followed by durvalumab for patients with Stage III NSCLC and a targetable tumor mutation
Track 20: Case: A woman in her early fifties with advanced “pan-negative” nonsquamous NSCLC experiences a near complete response with 1 dose of ipilimumab/nivolumab

Interview with Justin F Gainor, MD

Track 1: Case: A 76-year-old man and never smoker presents with metastatic NSCLC with an EGFR L858R tumor mutation, a low PD-L1 TPS and brain metastases and receives first-line osimertinib
Track 2: Activity and tolerability of first-line osimertinib
Track 3: Stereotactic radiosurgery, whole-brain radiation therapy (WBRT) and EGFR TKIs for patients with EGFR tumor mutations and brain metastases
Track 4: Incidence and pathophysiology of neurocognitive effects of WBRT
Track 5: Optimal sequencing of EGFR TKIs
Track 6: Mechanism of action, benefits and limitations of the second-generation EGFR inhibitor dacomitinib
Track 7: Investigational strategies for patients experiencing disease progression on osimertinib
Track 8: Bevacizumab with erlotinib as first-line therapy for patients with metastatic NSCLC and an EGFR tumor mutation
Track 9: Rationale for combining first- and third-generation EGFR TKIs to potentially treat tumors with resistance mutations
Track 10: Case: A 57-year-old woman and never smoker with crizotinib-refractory NSCLC with an ALK rearrangement receives alectinib
Track 11: Sequencing of ALK inhibitors for patients with metastatic NSCLC with an ALK rearrangement
Track 12: Second-line therapy options for patients with metastatic NSCLC with an ALK rearrangement
Track 13: Case: A 64-year-old woman and never smoker with NSCLC with brain and bone metastases initially treated with carboplatin/pemetrexed is found to harbor a RET rearrangement
Track 14: Case: A 48-year-old man with heavily pretreated nonsquamous NSCLC whose tumor is positive for an NTRK gene fusion receives entrectinib on a clinical trial
Track 15: Efficacy of the TRK inhibitors entrectinib and larotrectinib
Track 16: Case: A 71-year-old man and 35 pack-year smoker with metastatic nonsquamous NSCLC and a BRAF V600E tumor mutation, renal insufficiency and a high TPS receives dabrafenib/trametinib
Track 17: Consideration of immune checkpoint inhibitor-based regimens as second-line therapy for patients with metastatic disease and renal insufficiency
 
FACULTY
 
David R Spigel, MD
Chief Scientific Officer
Program Director
Lung Cancer Research
Sarah Cannon Research Institute
Nashville, Tennessee
 
Justin F Gainor, MD
Assistant Professor
Harvard Medical School
Attending Physician
Massachusetts General Hospital
Cancer Center
Boston, Massachusetts
 
EDITOR
 
Neil Love, MD
Research To Practice
Miami, Florida